Brokerages expect STRATA Skin Sciences Inc (NASDAQ:SSKN) to report earnings per share of ($0.01) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for STRATA Skin Sciences’ earnings. STRATA Skin Sciences reported earnings of ($0.10) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 90%. The business is expected to report its next quarterly earnings results on Monday, April 1st.
According to Zacks, analysts expect that STRATA Skin Sciences will report full-year earnings of ($0.22) per share for the current year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.04) per share, with EPS estimates ranging from ($0.09) to $0.01. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow STRATA Skin Sciences.
STRATA Skin Sciences (NASDAQ:SSKN) last announced its quarterly earnings results on Tuesday, November 13th. The medical device company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. STRATA Skin Sciences had a negative net margin of 18.33% and a negative return on equity of 18.83%. The firm had revenue of $7.89 million for the quarter, compared to analyst estimates of $7.64 million.
A number of research analysts have commented on SSKN shares. HC Wainwright set a $5.00 price objective on shares of STRATA Skin Sciences and gave the company a “buy” rating in a research note on Wednesday, October 10th. Northland Securities started coverage on shares of STRATA Skin Sciences in a research note on Monday, December 10th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of STRATA Skin Sciences from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Friday, November 16th. Five analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $4.92.
Shares of NASDAQ:SSKN opened at $2.88 on Monday. STRATA Skin Sciences has a 12 month low of $1.09 and a 12 month high of $3.88. The company has a current ratio of 4.54, a quick ratio of 4.03 and a debt-to-equity ratio of 0.22. The firm has a market cap of $88.68 million, a P/E ratio of 1.46 and a beta of 0.97.
Several large investors have recently modified their holdings of SSKN. Vanguard Group Inc boosted its holdings in shares of STRATA Skin Sciences by 3,605.7% in the third quarter. Vanguard Group Inc now owns 593,357 shares of the medical device company’s stock valued at $2,100,000 after acquiring an additional 577,345 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of STRATA Skin Sciences by 3,605.7% in the third quarter. Vanguard Group Inc. now owns 593,357 shares of the medical device company’s stock valued at $2,100,000 after acquiring an additional 577,345 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of STRATA Skin Sciences by 154.0% in the third quarter. Renaissance Technologies LLC now owns 745,583 shares of the medical device company’s stock valued at $2,639,000 after acquiring an additional 452,084 shares in the last quarter. EAM Investors LLC purchased a new stake in shares of STRATA Skin Sciences in the third quarter valued at about $830,000. Finally, Macquarie Group Ltd. boosted its holdings in shares of STRATA Skin Sciences by 89.7% in the second quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock valued at $275,000 after acquiring an additional 63,393 shares in the last quarter. 26.94% of the stock is currently owned by institutional investors and hedge funds.
STRATA Skin Sciences Company Profile
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.